- Home
- JVSA vs ALXO Comparison
JVSA vs ALXO Comparison
Compare JVSA & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JVSA
- ALXO
- Stock Information
- Founded
- JVSA 2021
- ALXO 2015
- Country
- JVSA Hong Kong
- ALXO United States
- Employees
- JVSA N/A
- ALXO N/A
- Industry
- JVSA
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- JVSA
- ALXO Health Care
- Exchange
- JVSA NYSE
- ALXO Nasdaq
- Market Cap
- JVSA 79.7M
- ALXO 81.1M
- IPO Year
- JVSA 2024
- ALXO 2020
- Fundamental
- Price
- JVSA $10.38
- ALXO $1.36
- Analyst Decision
- JVSA
- ALXO Strong Buy
- Analyst Count
- JVSA 0
- ALXO 6
- Target Price
- JVSA N/A
- ALXO $14.20
- AVG Volume (30 Days)
- JVSA 1.2K
- ALXO 851.1K
- Earning Date
- JVSA 01-01-0001
- ALXO 11-07-2024
- Dividend Yield
- JVSA N/A
- ALXO N/A
- EPS Growth
- JVSA N/A
- ALXO N/A
- EPS
- JVSA N/A
- ALXO N/A
- Revenue
- JVSA N/A
- ALXO N/A
- Revenue This Year
- JVSA N/A
- ALXO N/A
- Revenue Next Year
- JVSA N/A
- ALXO N/A
- P/E Ratio
- JVSA $58.13
- ALXO N/A
- Revenue Growth
- JVSA N/A
- ALXO N/A
- 52 Week Low
- JVSA $10.02
- ALXO $1.30
- 52 Week High
- JVSA $10.42
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- JVSA N/A
- ALXO 34.21
- Support Level
- JVSA N/A
- ALXO $1.44
- Resistance Level
- JVSA N/A
- ALXO $1.63
- Average True Range (ATR)
- JVSA 0.00
- ALXO 0.12
- MACD
- JVSA 0.00
- ALXO 0.02
- Stochastic Oscillator
- JVSA 0.00
- ALXO 13.43
About JVSA JVSPAC ACQUISITION CORP
JVSPAC Acquisition Corp is blank check company.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.